Found 10 resultsAuthor Title [ Type] Year
Filters: Author is Gordon, Ingelise J [Clear All Filters]
Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med, 376(10), 928-938. presented at the 2017 03 09. doi:10.1056/NEJMoa1410863. (2017).
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis, 11(12), 916-24. presented at the 2011 Dec. doi:10.1016/S1473-3099(11)70240-7. (2011).
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One, 8(4), e59340. presented at the 2013. doi:10.1371/journal.pone.0059340. (2013).
Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One, 10(4), e0123969. presented at the 2015. doi:10.1371/journal.pone.0123969. (2015).
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). PLoS One, 9(3), e91366. presented at the 2014. doi:10.1371/journal.pone.0091366. (2014).
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science, 341(6152), 1359-65. presented at the 2013 Sep 20. doi:10.1126/science.1241800. (2013).
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.. Vaccine, 25(8), 1513-25. presented at the 2007 Feb 09. doi:10.1016/j.vaccine.2006.10.047. (2007).
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine, 26(50), 6338-43. presented at the 2008 Nov 25. doi:10.1016/j.vaccine.2008.09.026. (2008).
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis, 207(12), 1829-40. presented at the 2013 Jun 15. doi:10.1093/infdis/jit098. (2013).
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis, 203(10), 1396-404. presented at the 2011 May 15. doi:10.1093/infdis/jir054. (2011).